BioViva USA Inc (BioViva) announces an exclusive collaboration with Integrated Health Systems Ltd (IHS) to analyze, store, and publish anonymized data from patients who are given access to consensual gene and cell therapies worldwide.
Today’s investors are wary of drug development taking decades because of unknown performance in humans. This time lag makes it difficult for small companies to survive while awaiting funding. To solve this problem and create an efficient translation of medicine, IHS will help patients get access to treatments, and BioViva will analyze the patient data to help investors know where to invest.
BioViva has built a Platform for Robust Omics Based Evidence (PROBE) for advanced gene and cell therapeutics. It will allow researchers and medical doctors to work together to safely and securely collect relevant data, which will give an indication as to how well the most promising therapies in regenerative medicine are working in patients. To this end, the BioViva/IHS teams are committed to the following:
Accelerated path to human trials: the BioViva/IHS collaboration is intended to provide biotech companies, doctors’ networks, researchers, and patients fast and efficient access to each other, taking years off therapeutic development, and meeting patient demand.
Bridging stakeholders with biotechnology: if a drug shows benefits, biotech companies will be able to use the data gained from the BioViva platform to access investors who want to de-risk biotechnology investing.
Growing knowledge base: the BioViva platform will collect and monitor patients’ data and note any changes in biomarkers as a response to treatments. BioViva will utilize the latest machine learning algorithms to validate these findings and develop critical knowledge as the data accumulates.
Creating dependability: doctor networks, biotech companies, and patients will come to depend on the benefits from the BioViva/IHS collaboration. The data will drive future innovations in therapeutic options and potential combinatorial therapies to tackle the world's biggest medical burden, disease.
Regenerative medicine is poised to have a large impact in the medical market sector over the next few years, accounting for billions of dollars spent on medical tourism. Many treatments are sold to patients with little data of how well they work or how long the beneficial effects will last. BioViva has spent years researching how best to get patients access to treatments, and how to ensure there is accurate data of what happens after treatment.
“This platform will expedite investments into drug development by years and therefore it can potentially save millions of lives,” states Liz Parrish, CEO of BioViva. “Investors will get better guidance before funding lengthy trials.”
BioViva is not a one drug company, it is a multi-drug platform to accelerate drug development, collect valuable patient data, and find combinatorial therapeutics that cure the diseases of aging.
In that respect, BioViva is a platform company with the principles as described in this release.
BioViva USA, Inc. - Delivering on patient access with analysis
Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
For Further Information, Contact:
BioViva USA Inc
PO Box 10843
Bainbridge Island WA 98110